Deal Watch: Gilead And Spring Bank Set Second Trial Collaboration In HBV
Analyst speculates that Gilead could move to acquire Spring Bank if combo trial yields promising data for functional cure of hepatitis B. Eisai in-licenses PARP inhibitor with potential in breast cancer from Oncology Venture, while Sunovion out-licenses three corticosteroid products to Covis.
You may also be interested in...
The summer slowdown finally seems to have hit the US biopharma IPO market; after a hot July with nine offerings, there were just two during the first half of August. Also, Zogenix leads recent follow-ons with a $312m offering; venture capital planted in UK biotechs – Orchard and Blueberry.
While current HBV drugs work well to suppress the virus, combination success in HIV and HCV is leading biopharmas to seek a multi-part approach to suppressing and clearing the virus, with limited-term therapy.
China will provide a rising market potential for Sanpower’s newly acquired Dendreon and its Provenge product for prostate cancer, as part of the Chinese firm’s broader strategy, and the deal could also have an impact on the regulatory climate for cellular immunotherapies in China.